Stifel raised the firm’s price target on Neurocrine (NBIX) to $183 from $174 and keeps a Buy rating on the share following a Q3 report the firm says was “highlighted by a clear Ingrezza beat, as well as another substantial beat on Crenessity.” The firm, which notes it previously raised its peak sales estimate for Crenessity in Q2, is again raising near-term estimates following “another exemplary quarter,” the analyst added.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine price target raised to $160 from $156 at RBC Capital
- Neurocrine price target raised to $146 from $145 at Mizuho
- Neurocrine price target raised to $147 from $124 at BMO Capital
- Neurocrine price target raised to $179 from $175 at Piper Sandler
- Neurocrine price target raised to $164 from $160 at Canaccord